Novartis India Limited has submitted its quarterly compliance certificate to BSE Limited under SEBI regulatory requirements for the quarter and financial year ended March 31, 2026. The pharmaceutical company filed the mandatory certificate as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the Registrar to an Issue and Share Transfer Agent for Novartis India Limited. The document was dated April 06, 2026, and subsequently filed with the stock exchange on April 13, 2026.

Certificate Confirmation

MUFG Intime India Private Limited confirmed that all securities received from depository participants for dematerialization during the quarter ended March 31, 2026, were properly processed within prescribed timelines. The registrar verified that security certificates received for dematerialization were confirmed or rejected appropriately, and that certificates were mutilated and cancelled after due verification by the depository participant.

The certificate also confirmed that the names of depositories were substituted in the register of members as registered owners within the prescribed timelines. Notably, the registrar reported that no requests for rematerialization were received during the quarter.

Corporate Information

Novartis India Limited operates from Inspire BKC, 7th Floor, Bandra Kurla Complex, Bandra East, Mumbai. The company's securities are listed on BSE Limited under scrip code 500672. The compliance certificate was signed by Chandni Maru, Company Secretary and Compliance Officer, demonstrating the company's commitment to maintaining proper regulatory adherence.

This routine filing reflects the company's ongoing compliance with SEBI regulations governing depositories and participants, ensuring transparent and proper handling of securities transactions during the reporting period.

Novartis India Limited has issued a regulatory notice regarding its postal ballot and e-voting process, fulfilling mandatory disclosure requirements under securities regulations. The pharmaceutical company published newspaper advertisements on April 13, 2026, to inform shareholders about the upcoming postal ballot procedure.

Regulatory Compliance Notice

The company filed a formal intimation with BSE Limited regarding the publication of newspaper advertisements in Financial Express and Navshakti. The notice was submitted pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Corporate Communication Details

Company Secretary and Compliance Officer Chandni Maru signed the regulatory communication on behalf of Novartis India Limited. The notice was digitally signed and submitted to BSE Limited's corporate communications department.

Postal Ballot Process Framework

The postal ballot process will be conducted in accordance with multiple regulatory frameworks, including Sections 110 and 108 of the Companies Act, 2013, and Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014. The company will also follow SEBI Listing Regulations and Secretarial Standards on General Meetings issued by The Institute of Company Secretaries of India.

Shareholder Communication Protocol

The notice will be distributed electronically to all members whose email addresses are registered with the company or Depository Participants. The postal ballot notice will also be made available on the company's website at www.novartis.in and on BSE Limited's website at www.bseindia.com .

Registration and Compliance Requirements

Shareholders holding shares in physical mode can register their email addresses with the company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited. The registration process requires completion of Form ISR-1 along with supporting documents including PAN and Aadhaar card copies. Email registration is contingent upon completion of KYC requirements as per SEBI regulations.